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Asthma is a chronic inflammatory disease of the airways. Asthmatics are at risk of 
developing structural changes resulting in persistent airflow limitations and 
remodeling.1 On average, asthma patients have lower lung function than healthy 
individuals and their lung function (FEV1) decline can be greater over time.1 
Nevertheless, not all asthma patients decline over time; some show stable lung 
function while others can outgrow their asthma disease.2 Previous studies have 
revealed risk factors for accelerated FEV1 decline in asthma including airway 
inflammation. Indeed, high eosinophil sputum numbers,2 as well as higher blood 
eosinophil numbers3 have been linked to the accelerated rate of lung function decline 
in asthma. Analysis of exhaled breath for endogenously generated volatile organic 
compounds (VOCs) has previously been found to be able to noninvasively differ-
entiate eosinophilic from neutrophilic asthma.4 In a previous study, we were also able 
to identify in vitro VOCs discriminating between eosinophil and neutrophil cultures, 
regardless the activation status.5 As VOCs are able to reflect inflammation,4 we were 
interested to evaluate if VOCs are able to quantify airflow decline in asthma. VOC 
measurements could be an easy and non-invasive way to identify ongoing airflow 
decline in asthmatic for whom no prior measurement of lung function was available. 
This could have an impact on the follow-up visit schedule and treatment regimen.
We conducted a prospective study on a population of unselected asthmatics 
recruited from the University Asthma Clinic of Liege after gaining fully informed 
written consent and with approval from the ethics committee of CHU Liège (2005/ 
181) in accordance with the Helsinki Declaration. Patients underwent measurements 
of fraction of exhaled nitric oxide (FeNO), spirometry, sputum induction, and gave 
a blood sample at two time points (baseline and 5 years later). VOC measurements 
were collected once at the 5-year-follow-up visit. Subjects with asthma were allo-
cated in two groups (airflow decliners and non-decliners) retrospectively according to 
their lung function (post-BD FEV1) decline per year calculated as by subtracting the 
follow-up measured value from the baseline post-BD FEV1, subdivided by the 
number of months separating the two measurements, and multiplied by 12. Decline 
was defined as a loss of FEV1 (% predicted)/year greater than zero. The thermal 
desorption tubes, containing the exhaled breath of the patients were desorbed onto 
a Pegasus 4D HRT (LECO Corporation, St. Joseph, MI, USA) GC × GC-HR ToF MS 
instrument with an Agilent 7890 GC equipped with a TD100-xr thermal desorber 
(Markes International Ltd.). The data were acquired and analyzed using ChromaTOF 
HRT software, version 5.20 (LECO Corporation) and GC Image software version 
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2.5HRMS®. Analysis of the data output files was performed 
in successive steps as previously described.6 The identifica-
tion of the VOCs was performed following high analytical 
standards (bi-dimensional chromatographic retention times 
and mass spectral matching factors). To estimate the dis-
crimination importance of each VOC, conditional inference 
forest algorithm7 along with variable importance measure 
were used to assess the discriminatory power of each VOC 
in the different scenarios. Receiver operating characteristic 
(ROC) curves were constructed to assess the discriminatory 
power of the biomarkers for lung function decline.
Exhaled breath of 45 asthmatics was analyzed. Patient 
characteristics and baseline lung function parameters are 
presented in Table 1. Twenty-five patients (56%) were air-
flow decliners over a 5-year period and 20 patients (44%) 
were non-decliners. Looking at baseline characteristics, we 
did not find any significant difference between groups 
regarding gender, age, age of onset, BMI, smoking history, 
baseline FEV1, FeNO, sputum eosinophil and neutrophil 
counts, Asthma Control Questionnaire or blood eosinophils 
Table 1 Demographic, Clinical and Inflammatory Characteristics 
at Baseline of Asthmatics with VOC Measurements (n=45)
Characteristics No Decline Airflow 
Decline
p-value
N (%) 25 (56) 20 (44)
Women (%) 13 (65) 15 (60) 0.767
Age (years) 48 ± 13 53 ± 14 0.2380
BMI (kg/m2) 25 ± 3 26 ± 4 0.6842
Atopy (Y) (%) 10 (53) 12 (50) 0.999
Smoking status (%)
● Never smokers 9 (45) 12 (52) 0.483
● Current smokers 6 (30) 3 (13)
● Ex-smokers 5 (25) 8 (35)
Age of onset (years) 37 ± 15 38 ± 22 0.9296
Disease duration (years) 11 ± 16 17 ± 14 0.2150
Post-BD FEV1 (L) 2.65 ± 0.98 2.38 ± 0.72 0.2830
Post-BD FEV1/FVC (% 
pred)
74 ± 11 67 ± 12 0.0494
Reversibility (%) 4.32 ± 6.29 7.48 ± 7.93 0.1601
ACT score 13 ± 5.5 16.7 ± 5.2 0.0455
ACQ score 2.5 ± 1.4 2.0 ± 1.1 0.2343
AQLQ score 4.1 ± 1.5 4.4 ± 1.4 0.3979
FeNO (ppb) 39 (16–71) 29 (19–45) 0.6473
Sputum eosinophil count 
(% of non-squamous 
cells)
4.3 (0.1–50.7) 3.4 (0.8–5.4) 0.4155
Sputum neutrophils 







Blood eosinophils (/µL) 223 
(116–594)
162 (92−228) 0.1534





Total serum IgE (kU/L) 126 (66–280) 191 (49–489) 0.4587
CRP (mg/L) 2 (1–6) 2 (0.5–5) 0.6289
Fibrinogen (g/L) 4 (3–4) 4 (3–4) 0.8299







Table 1 (Continued). 
Characteristics No Decline Airflow 
Decline
p-value
● Steroid naïve 5 (25%) 6 (25%) 0.349
● Low dose 1 (5%) 2 (8%)
● Medium dose 7 (35%) 3 (12%)
● High dose 5 (25%) 13 (54%)
LABA, N (%) 15 (75) 15 (60) 0.352
LAMA, N (%) 1 (5) 5 (20) 0.205
OCS therapy, N (%) 2 (10) 4 (16) 0.678
Biologic therapy (anti- 
IgE)
0 (0) 1 (4) 1.000
Exacerbations in 
previous year
1 (0–1) 1 (0–1) 0.5916
Hospitalizations in 
previous year
0 (0–1) 0 (0–1) 0.9371
Notes: Comparison between airflow decline (FEV1 decline (% predicted)/year >0) 
and no decline groups in asthma. Data are presented as mean ±SD or median and 
IQR. Low-dose ICS: <500μg/day; moderate-dose ICS: >500–1000μg/day; high-dose 
ICS: > 1000 μg/day beclomethasone dipropionate – chlorofluorocarbon. 
Abbreviations: BMI, body mass index; BD, bronchodilation; FEV1, forced expira-
tory volume in 1s; FVC, forced vital capacity; ACT, Asthma Control Test; ACQ, 
Asthma Control Questionnaire; AQLQ, Asthma Quality of Life Questionnaire; 
FeNO, fractional exhaled nitric oxide; ppb, parts per billion; ICS, inhaled corticos-
teroid; LABA, long-acting ß2-agonist; LAMA, long-acting muscarinic antagonist; 
OCS, oral corticosteroid.
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and neutrophils, exacerbations, hospitalizations in the last 
12 months, or treatment regimen. Fifty-four percent of air-
flow decliners were receiving high ICS daily doses, as 
compared to 25% in the non-decliners. OCS maintenance 
treatment was present in 16% of airflow decliners versus 
10% in non-decliners. Sixty percent of decliners and 75% of 
non-decliners were treated with long-acting β2 agonists. 
Twenty percent of decliners versus 5% of non-decliners 
were receiving long-acting anti-muscarinic agent therapy.
According to ERS/ATS criteria,8 40% of these patients 
were severe asthmatics. Eight of them were started on 
biologic therapy during the study. Three of them were 
still part of the airflow decliners group. Sputum inflamma-
tory phenotypes and inhaled corticosteroid doses were 
quite stable over time.
Based on a set of 640 VOCs, the comparison of these 
two groups revealed no difference between airflow decli-
ners and non-decliners. Moreover, no difference between 
groups was observed based on the 25 VOCs with the 
highest classification performance. With a Random 
Forest estimated prediction error of 48.6%, no significant 
discrimination could neither be shown between the two 
groups. ROC curves for the prediction of FEV1 decline 
using 5, 10, 15, 25, 50, 100 VOCs had AUC of 0.529, 
0.533, 0.545, 0.538, 0.547, 0.544, respectively (Figure 1).
Although Lazar et al9 previously found that broncho-
constriction after methacholine challenge did not affect 
Breathprint using eNose, we hypothesized that VOCs 
could discriminate between airflow decliners and non- 
decliners as several cytokines and inflammatory cells 
may play a role in airflow decline. Our study is the first 
attempt to relate exhaled VOC profiles to lung function 
decline in asthmatic patients over 5 years. According to 
our results, VOCs are not able to discriminate between 
airflow decliners and non-decliners. In our study, airflow 
decliners and non-decliners had similar levels of FeNO, 
Figure 1 Area under the receiver operating characteristic curves from the conditional inference forest binary classification of decliners versus non-decliners using 5, 10, 15, 
25, 50, 100 VOCs of highest classification performance. 
Abbreviation: AUC, area under the curve.
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blood and sputum eosinophils at baseline. It has already 
been shown that VOCs reflect airway inflammation.4 Our 
observations bring out that exhaled VOCs are possibly 
more to be considered as a reflection of the inflammatory 
mechanism rather than an airway caliber. Our results 
should be confirmed in a larger cohort using multiple 
VOC measurements over a longer period of time to see 
if the change in VOC levels over time can reflect FEV1 
decline and if other variables may affect the relationship 
between VOC measurements and lung function.
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